



(51) **International Patent Classification:**
C07D 333/20 (2006.01) **A61P 25/00** (2006.01)
A61K 31/381 (2006.01)

(21) **International Application Number:**
PCT/EP2008/066137

(22) **International Filing Date:**
25 November 2008 (25.11.2008)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**
07121795.4 28 November 2007 (28.11.2007) EP
60/990,721 28 November 2007 (28.11.2007) US
08166576.2 14 October 2008 (14.10.2008) EP

(71) **Applicant (for all designated States except US):**
SCHWARZ PHARMA AG [DE/DE]; Alfred-Nobel-Strasse 10, 40789 Monheim (DE).

(72) **Inventors; and**

(75) **Inventors/Applicants (for US only):** **WOLFF, Hans-Michael** [DE/DE]; Schwarz Biosciences GmbH, Alfred-Nobel-Strasse 10, 40789 Monheim (DE). **QUERE, Luc** [BE/BE]; UCB Pharma SA, Chemin du Foriest, B-1420 Braine-l'Alleud (BE). **RIEDNER, Jens** [BE/BE]; UCB Pharma SA, Chemin du Foriest, B-1420 Braine-l'Alleud (BE).

(74) **Agent:** **HOFFMANN EITLE**; Arabellastrasse 4, 81925 München (DE).

(81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) **Date of publication of the international search report:**
24 September 2009

(54) **Title:** POLYMORPHIC FORM OF ROTIGOTINE




Figure 1 Experimental powder X-ray diffractogram of novel polymorphic form (II) of Rotigotine

(57) **Abstract:** The present invention relates to a novel polymorphic form of Rotigotine characterized by at least one of the following X-ray powder diffraction peaks: 12.04, 13.68, 17.72 and 19.01 ± 0.2 ($^{\circ}2\theta$), measured with a Cu-K $_{\alpha}$ irradiation (1.54060 Å), and a process for production thereof, which is useful for the manufacture of a stable medicament for treating or alleviating symptoms of Parkinson's Disease and other dopamine-related disorders.